Dossier assessment
Dupilumab (eosinophilic oesophagitis, 1 to 11 years) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Dupilumab (eosinophilic oesophagitis, 1 to 11 years) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Dupilumab (eosinophilic oesophagitis, 1 to 11 years) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Children 1 to 11 years of age, weighing at least 15 kg, with eosinophilic oesophagitis who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy
Added benefit not proven
Project details
- Project no.
- A24-117
- Commission
- Commission awarded on 29.11.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A24-117_en
Connected Projects
-
Dossier assessment
Dupilumab (COPD) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (eosinophilic oesophagitis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (prurigo nodularis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (atopic dermatitis, 6 months to 5 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (severe asthma with type 2 inflammation) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (atopic dermatitis in children) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (atopic dermatitis in adolescents) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V
Status: Commission completed
-
Dossier assessment
Dupilumab (chronic spontaneous urticaria in children >= 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dupilumab (chronic spontaneous urticaria in adults and adolescents 12 years and above) – Benefit assessment according to §35a
Status: Commission completed